Astrana Health Inc
NASDAQ: ASTH · HEALTHCARE · MEDICAL CARE FACILITIES
Updated 2026-06-05
Astrana Health Inc (ASTH) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for ASTH.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
ASTH historical valuation range
Where current P/E sits in ASTH's own 5Y range.
ASTH intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
ASTH valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 61.67x
P/S Ratio — History
Current: 0.53x
Is ASTH overvalued in 2026?
Astrana Health Inc (ASTH) currently trades at $37.97 per share with a market capitalization of $1,865,328,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 56/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 61.7x, above its 5-year median of 47.9x.
Looking at its own history, ASTH is currently trading more expensive than 69% of the last 5Y on P/E. This places it in the 69th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates ASTH's intrinsic value at $188.57 per share, against the current market price of $37.97. This implies a margin of safety of +89.91%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
Financial quality is a concern. The Piotroski F-Score of 1/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: ASTH trades at a fair valuation on our framework, with a Smart Value Score of 56/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is ASTH overvalued?
ASTH scores 56/100 on our Smart Value Score (Grade C+), a mixed overall profile. The DCF also shows a positive margin of safety, so price and fundamentals line up reasonably well.
What is ASTH's fair value?
Our DCF model estimates ASTH's intrinsic value at $188.57 per share, versus the current price of $37.97, a margin of safety of +89.91%. Fair value is the present value of the cash flows we project the business to produce, so a price below it means the market is pricing the stock below that conservative estimate.
What P/E ratio does ASTH trade at?
ASTH trades at a P/E of 61.7x on trailing twelve-month earnings, against a 5-year median of 47.9x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.
Is ASTH a buy based on valuation?
Our Smart Value rating for ASTH is Hold, from a Smart Value Score of 56/100 that blends growth, quality, and valuation. The profile is balanced and best suited to investors who already have a thesis. This is research to inform your decision, not personalized financial advice.
How does ASTH's valuation compare to its history?
On P/E, ASTH sits in the 69th percentile of its own 5Y range, above its long-run median relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.
What is ASTH's Smart Value Score?
ASTH's Smart Value Score is 56/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.